Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy Soligenix (Nasdaq: SNGX) reported that a 12-week comparability study of HyBryte (synthetic hypericin) versus Valchlor showed faster, more robust responses and a benign safety profile for HyBryte.At 12 weeks, 60% of HyBryte patients met the predefined treatment success (≥50% mCAILS improvement) versus 20% for Valchlor; mean mCAILS improvement was 52.5% vs 34.7%. HyBryte had no therapy-related adverse events; Valchlor had related AEs in 60% and one withdrawal for allergic contact dermatitis.

#SNGX Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy

www.stocktitan.net/news/SNGX/positive-clini...

Soligenix Highlights Year-End 2025 Financial Results and Strategic Milestones Ahead Soligenix has reported its financial results for 2025, announcing crucial milestones in its clinical trials and ongoing commitment to rare diseases.

Soligenix Highlights Year-End 2025 Financial Results and Strategic Milestones Ahead #USA #Princeton #Soligenix #HyBryte #SNGX

Soligenix says pivotal HyBryte trial readouts arrive in 2026 Net loss widened to $11.1M as R&D rose to $7.5M. Why it matters: cash lasts into Q4 2026, with a HyBryte Phase 3 interim analysis due in Q2.

#SNGX Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results

www.stocktitan.net/news/SNGX/soligenix-anno...

Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease Soligenix (Nasdaq: SNGX) announced the European Commission granted orphan drug designation to dusquetide (active in SGX945) for the treatment of Behçet's Disease on March 26, 2026. The decision followed a positive EMA COMP recommendation and Phase 2a results showing biological efficacy and safety.The designation complements prior FDA orphan and fast track statuses, offers a 10-year EU marketing exclusivity after approval, and provides protocol assistance and centralized authorization access for development.

#SNGX Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease

www.stocktitan.net/news/SNGX/soligenix-rece...

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026 Soligenix (Nasdaq: SNGX) announced that supportive data for HyBryte™ (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL) will be presented at the US Cutaneous Lymphoma Consortium Workshop on March 26, 2026.Presentations include a Phase 2 real-world long-term treatment study by Dr. Ellen Kim and a pilot comparability poster versus Valchlor® by Dr. Brian Poligone, reporting improved outcomes with longer treatment and favorable tolerability versus mechlorethamine.

#SNGX HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

www.stocktitan.net/news/SNGX/hy-bryte-tm-tr...

Skin lymphoma drug review spotlights safety as Phase 3 enrollment nears Author reviewed four HyBryte studies and called it a potential first-line option for early-stage CTCL; FLASH2 interim data is due in 2Q 2026.

#SNGX Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"

www.stocktitan.net/news/SNGX/soligenix-anno...

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency Soligenix (Nasdaq: SNGX) announced on March 10, 2026 that SGX945 (dusquetide) received Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for the treatment of Behçet's Disease. The PIM designation is a prerequisite for consideration in the UK Early Access to Medicines Scheme (EAMS). Soligenix cited Phase 2 Behçet's clinical data and prior oral mucositis study consistency as the basis for the designation. Management said it will work with the MHRA to pursue EAMS access and potentially enable earlier patient availability.

#SNGX Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

www.stocktitan.net/news/SNGX/soligenix-anno...

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease Soligenix (Nasdaq: SNGX) announced the EMA Committee for Orphan Medicinal Products (COMP) gave a positive opinion on its request for orphan drug designation for dusquetide (SGX945) to treat Behçet's Disease, following Phase 2a results showing biological efficacy and safety. The opinion must be ratified by the European Commission.SGX945 previously received FDA orphan drug and fast track designations. EMA orphan status would provide 10 years of EU marketing exclusivity after approval and access to centralized authorization and protocol assistance.

#SNGX Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease

www.stocktitan.net/news/SNGX/soligenix-rece...

#SNGX Published Phase 2a results for SGX945 add clinical validation to Soligenix's Behçet’s disease program.

#BiotechStocks #SmallCaps #ClinicalTrials

youtu.be/hnrktxdh52g

#SNGX: Positive Results for Phase 2a Trial in Psoriasis buff.ly/gVSMjlb

#biotech #lymphoma #CTCL

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) Soligenix (Nasdaq: SNGX) announced publication of Phase 2a results for SGX945 (dusquetide) in Behçet's Disease (oral aphthous ulcers) on December 18, 2025. In an open-label pilot (n=8) SGX945 showed beneficial effects for 7 of 8 patients during 4 weeks of treatment and maintained effects through a 4-week follow-up.Using the apremilast Phase 3 AUC endpoint, SGX945 showed a 40% improvement at Week 4 versus placebo (apremilast 37%) and a 32% improvement at Week 8 despite treatment stopping at Week 4 (apremilast 41% at Week 8). No treatment-related adverse events reported.

#SNGX Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

www.stocktitan.net/news/SNGX/positive-clini...

Trade Alerts, Wednesday December 17, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Wed Dec 17th - #SNGX #DFSC #VTGN #PLCE #KYTX #IMNM #SPIR - More: crystalequityresearch.com/trade-alerts... - #smallcap

#SNGX Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

www.stocktitan.net/news/SNGX/soligenix-anno...

Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad Soligenix (NASDAQ: SNGX) announced placement in an editorial published by BioMedWire on Dec 5, 2025, highlighting the growing rare-disease burden among aging U.S. populations and the need for novel therapies.The company is described as a late-stage biopharmaceutical developer advancing multiple rare-disease programs, including HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma, which is stated to be in its final confirmatory trial before seeking global marketing authorization.The piece frames Soligenix’s programs at a pivotal intersection of scientific innovation and national health-policy focus on chronic and rare diseases.

#SNGX Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

www.stocktitan.net/news/SNGX/soligenix-inc-...

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space Soligenix (NASDAQ: SNGX) announced placement in an editorial highlighting chronic rare diseases and the role of its lead therapy HyBryte (synthetic hypericin) for cutaneous T‑cell lymphoma (CTCL).The company is described as a late‑stage biopharmaceutical conducting the final confirmatory clinical study required before filing for worldwide marketing approval for HyBryte. The piece places Soligenix at the intersection of medical innovation and federal health policy amid rising rare‑disease burdens, noting that more than 30 million Americans are affected by rare diseases (NIH figure).

#SNGX Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

www.stocktitan.net/news/SNGX/soligenix-inc-...

#SNGX: Phase 3 FLASH2 Trial Enrolls 50th Patient; Interim Analysis in 2Q26 buff.ly/XGoMNe3

#SNGX: DMC Reports No Safety Signals for Ongoing Phase 3 Trial in CTCL; Blinded Interim Efficacy Analysis in 1H26 buff.ly/Z2buiHt

Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results PRINCETON, N.J., Nov. 7, 2025/ PRNewswire/-- Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2025.. Schaber continued, "With approximately...

#SNGX Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results

www.stocktitan.net/news/SNGX/soligenix-anno...

#SNGX: Public Offering Raises $7.5 Million; Expands European Medical Advisory Board buff.ly/wSx23hP

Soligenix Completes $7.5 Million Public Offering to Drive Future Growth and Development Soligenix, Inc. has successfully closed its $7.5 million public offering, aimed at funding key developments in rare disease treatments and extending its cash runway.

Soligenix Completes $7.5 Million Public Offering to Drive Future Growth and Development #USA #Princeton #Biopharmaceutical #Soligenix #SNGX

Breakthrough: First Ebola Vaccine Stable for 2 Years at High Heat - Soligenix's Game-Changing Discovery Biotech firm demonstrates long-term stability of bivalent and trivalent Ebola vaccines at 40°C/104°F. ThermoVax platform shows promise for COVID and other vaccines without cold storage.

#SNGX Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

www.stocktitan.net/news/SNGX/soligenix-anno...

#SNGX Dusquetide (SGX945) Granted Orphan Drug Designation for Behcet’s Disease buff.ly/pNFYwDR

Most Searched, Monday August 18, 2025 – Crystal Equity Research

Most searched small-cap stocks, Mon Aug 18th - #BSGM #DAWN #SNGX #OPEN #WULF #WRD #SBET #MGNX #LUNR #HIVE #SHCO #ONDS #ARRY #CIFR #DNN #GDRX #VTAK #FFAI #PPCB - More: crystalequityresearch.com/most-searche... - #smallcap

News; ( NASDAQ: #SNGX ) US Companies Moving the Markets, Evening edition <br>Mon, Aug 18, 2025 as of 4:00 pm ET

Breaking News: ( NASDAQ: #SNGX ) BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Beh et's Disease

18,000 U.S. Patients: Soligenix's Rare Disease Drug SGX945 Wins Critical FDA Orphan Status for Behçet's FDA grants orphan drug designation to Soligenix's dusquetide (SGX945) for Behçet's Disease, affecting 18,000 U.S. patients. Offers 7-year market exclusivity upon approval following Phase 2 results.

#SNGX FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

www.stocktitan.net/news/SNGX/fda-grants-sol...

Soligenix Nears Key Clinical Trial Results as Q2 Expenses Rise on Drug Development Progress Biotech firm reports increased R&D spending on rare disease trials, maintains $6.5M cash position. Phase 2a success in Behçet's Disease, multiple trial readouts ahead. Get details.

#SNGX Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results

www.stocktitan.net/news/SNGX/soligenix-anno...

Breakthrough CTCL Cancer Treatment: Soligenix Advances US-Made HyBryte Platform as Aging Population Surges Soligenix's HyBryte platform addresses 30M+ rare disease patients with US-based manufacturing of innovative CTCL therapy. Learn about this breakthrough treatment.

#SNGX Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy

www.stocktitan.net/news/SNGX/soligenix-inc-...

Breakthrough: Soligenix's Rare Disease Treatment HyBryte Achieves Major Manufacturing Milestone for CTCL Therapy Soligenix's HyBryte platform targets 30M+ rare disease patients with successful US-based manufacturing of CTCL treatment. See development timeline.

#SNGX Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

www.stocktitan.net/news/SNGX/soligenix-inc-...